Glia Pharm

Curated by Signal

Developer of treatments for neurological and psychiatric disorders

Overview

Developer of treatments for neurological and psychiatric disorders. The company seeks to develop neuroactive agents that target Glial Cells and Astrocytes with treatment potential in a variety of pathologies, including cognitive impairments of various origins, neurodegenerative diseases, multiple sclerosis, epilepsy, depression, and migraine.

Key facts

Founded: 2016
Headquarters: Lausanne, Switzerland
Stage: Sign up to view
Industry: Life Sciences Technology

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

NeuroPro
Developer of device for monitoring brain signals
Life Sciences TechnologyZurich, Switzerland
TOLREMO therapeutics
Developing anti-cancer small molecules targeting novel drug resistance pathways
Life Sciences TechnologyZurich, Switzerland
Ascensia
Developer of glucose monitoring systems and diabetes management software
Life Sciences TechnologyBasel, Switzerland

About Glia Pharm

What does Glia Pharm do?

Developer of treatments for neurological and psychiatric disorders.

Where is Glia Pharm headquartered?

Glia Pharm is headquartered in Lausanne, Switzerland.

When was Glia Pharm founded?

Glia Pharm was founded in 2016.

Which sector is Glia Pharm in?

Glia Pharm operates in Life Sciences Technology.

Who are Glia Pharm's competitors?

Companies similar to Glia Pharm include NeuroPro, TOLREMO therapeutics, and Ascensia.